These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 28694672)
61. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. Toshida K; Itoh S; Yoshizumi T; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oki E; Nakamura Y; Yoshino T; Mori M Clin J Gastroenterol; 2021 Oct; 14(5):1459-1463. PubMed ID: 34085164 [TBL] [Abstract][Full Text] [Related]
62. Intrahepatic cholangiocarcinoma: the role of imaging in detection and staging. Kuszyk BS; Soyer P; Bluemke DA; Fishman EK Crit Rev Diagn Imaging; 1997; 38(1):59-88. PubMed ID: 9063621 [TBL] [Abstract][Full Text] [Related]
63. Intrahepatic cholangiocarcinoma and hepatitis: case study and literature review. Luh F; Kuei A; Fann P; Chu P; Yen Y Anticancer Res; 2009 Aug; 29(8):3239-43. PubMed ID: 19661341 [TBL] [Abstract][Full Text] [Related]
64. A case of concomitant colitic cancer and intrahepatic cholangiocarcinoma during follow-up for ulcerative colitis. Tsuchiya K; Nanashima A; Ikeda T; Minami S; Nagano M; Hamada T; Yano K; Fujii Y Clin J Gastroenterol; 2017 Apr; 10(2):157-162. PubMed ID: 28138905 [TBL] [Abstract][Full Text] [Related]
65. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma. Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137 [TBL] [Abstract][Full Text] [Related]
66. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Asayama Y; Yoshimitsu K; Irie H; Tajima T; Nishie A; Hirakawa M; Nakayama T; Kakihara D; Taketomi A; Aishima S; Honda H Radiology; 2006 Jan; 238(1):150-5. PubMed ID: 16304089 [TBL] [Abstract][Full Text] [Related]
67. Cholangiocarcinoma arising from preexisting biliary hamartoma of liver--report of a case. Orii T; Ohkohchi N; Sasaki K; Satomi S; Watanabe M; Moriya T Hepatogastroenterology; 2003; 50(50):333-6. PubMed ID: 12749215 [TBL] [Abstract][Full Text] [Related]
69. Multidetector computed tomography in the preoperative workup of hilar cholangiocarcinoma. Kim HJ; Lee DH; Lim JW; Ko YT Acta Radiol; 2009 Oct; 50(8):845-53. PubMed ID: 19639473 [TBL] [Abstract][Full Text] [Related]
70. Focal nodular hyperplasia-like lesion in a cirrhotic liver mimicking a cholangiocarcinoma. Loh JT; Chea YW; Lim KH; Wan WK; Wong JS J Clin Pathol; 2014 Apr; 67(4):377-80. PubMed ID: 24357439 [No Abstract] [Full Text] [Related]
71. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma. Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654 [TBL] [Abstract][Full Text] [Related]
72. Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. Sadot E; Simpson AL; Do RK; Gonen M; Shia J; Allen PJ; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR PLoS One; 2015; 10(7):e0132953. PubMed ID: 26207380 [TBL] [Abstract][Full Text] [Related]
73. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490 [TBL] [Abstract][Full Text] [Related]
74. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Kim YH; Hong EK; Kong SY; Han SS; Kim SH; Rhee JK; Hwang SK; Park SJ; Kim TM Oncotarget; 2016 Apr; 7(17):23825-36. PubMed ID: 27009864 [TBL] [Abstract][Full Text] [Related]
75. The role of microRNAs in intrahepatic cholangiocarcinoma. Li Z; Shen J; Chan MT; Wu WK J Cell Mol Med; 2017 Jan; 21(1):177-184. PubMed ID: 27619971 [TBL] [Abstract][Full Text] [Related]
76. Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings. Han JK; Choi BI; Kim AY; An SK; Lee JW; Kim TK; Kim SW Radiographics; 2002; 22(1):173-87. PubMed ID: 11796906 [TBL] [Abstract][Full Text] [Related]
77. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma. Li H; Zhou ZQ; Yang ZR; Tong DN; Guan J; Shi BJ; Nie J; Ding XT; Li B; Zhou GW; Zhang ZY Hepatology; 2017 Jul; 66(1):136-151. PubMed ID: 28194813 [TBL] [Abstract][Full Text] [Related]
78. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104 [TBL] [Abstract][Full Text] [Related]
79. A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Liu W; Chen JR; Hsu CH; Li YH; Chen YM; Lin CY; Huang SJ; Chang ZK; Chen YC; Lin CH; Gong HY; Lin CC; Kawakami K; Wu JL Hepatology; 2012 Dec; 56(6):2268-76. PubMed ID: 22729936 [TBL] [Abstract][Full Text] [Related]
80. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Kang YK; Kim WH; Lee HW; Lee HK; Kim YI Lab Invest; 1999 Apr; 79(4):477-83. PubMed ID: 10212000 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]